Although GLP-1 remains central to T2D therapy due to robust insulinotropic and cardiometabolic properties, PYY offers an additional therapeutic profile with hypothalamic appetite inhibition, delayed gastric emptying, enhanced insulin sensitivity, and possible islet-preserving effects. This evidence concerns the gene INS and type 2 diabetes mellitus.